Study on the Effects of Povetacicept for Adults with IgA Nephropathy

3 1

What is this study about?

This clinical trial is focused on studying a kidney disease called Immunoglobulin A Nephropathy (IgAN). This condition affects the kidneys and can lead to kidney damage over time. The study will test a treatment called Povetacicept Injection, which is given as a solution for injection under the skin. The purpose of the study is to see how effective Povetacicept is in reducing the amount of protein in the urine and in preserving kidney function compared to a placebo.

Participants in the study will receive either the Povetacicept Injection or a placebo. The study will last for a total of 104 weeks, which is about two years. During this time, participants will have regular check-ups to monitor their kidney function and the amount of protein in their urine. The study aims to see if Povetacicept can help slow down the progression of kidney disease in people with IgAN.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how well the treatment is working. The results of this study could provide valuable insights into new treatment options for people living with Immunoglobulin A Nephropathy.

1 initial visit

Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on specific criteria, such as a diagnosis of Immunoglobulin A Nephropathy (IgAN) and certain kidney function measurements.

You will receive detailed information about the study, including the purpose, procedures, and potential risks and benefits. You will have the opportunity to ask questions and provide informed consent to participate.

2 baseline assessments

Baseline assessments will be conducted to gather initial data. These assessments may include blood tests, urine tests, and measurements of kidney function.

The results will serve as a reference point to evaluate changes during the study.

3 randomization

You will be randomly assigned to receive either the study medication, povetacicept, or a placebo. A placebo is a substance with no active ingredients, used to compare the effects of the study medication.

This process is double-blind, meaning neither you nor the study team will know which treatment you are receiving.

4 treatment phase

During the treatment phase, you will receive povetacicept or placebo through a subcutaneous injection (an injection under the skin).

The injections will be administered according to the study schedule, which will be explained to you in detail. The treatment phase will last up to 104 weeks.

5 regular follow-up visits

You will attend regular follow-up visits to monitor your health and the effects of the treatment. These visits will include assessments similar to the baseline assessments.

The frequency of these visits will be outlined in the study schedule provided to you.

6 end of treatment assessments

At the end of the treatment phase, final assessments will be conducted to evaluate the effects of the study medication on your condition.

These assessments will help determine the efficacy of povetacicept in reducing protein levels in urine and preserving kidney function.

7 study completion

After completing the study, you will receive information about the overall results and any next steps regarding your health care.

Your participation will contribute to understanding the treatment of Immunoglobulin A Nephropathy.

Who Can Join the Study?

Must have a diagnosis of Immunoglobulin A Nephropathy (IgAN), confirmed by a kidney biopsy.
Must have a 24-hour urine protein excretion of at least 1.0 gram per day, or a 24-hour urine protein-to-creatinine ratio (uPCR) of at least 0.75 grams per gram.
Must have an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73m². This is a measure of how well the kidneys are filtering blood.
Must be on a stable dose of an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB), which are types of medications used to treat high blood pressure and kidney problems.
Both males and females are eligible to participate.
Participants must be within the specified age range for the study.

Who Cannot Join the Study?

Patients with any other kidney disease besides Immunoglobulin A Nephropathy cannot participate.
Patients who have had a kidney transplant are not eligible.
Patients with severe liver disease cannot join the study.
Patients with uncontrolled high blood pressure are excluded.
Patients who are pregnant or breastfeeding cannot participate.
Patients with a history of cancer in the last 5 years are not eligible.
Patients with a known allergy to the study medication cannot join.
Patients who are currently participating in another clinical trial are excluded.
Patients with a history of drug or alcohol abuse in the last year cannot participate.
Patients with any serious medical condition that might interfere with the study are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Technische Universitaet Dresden	Dresden	Germany
Katholieke Universiteit te Leuven	Leuven	Belgium
Oslo Universitetssykehus HF	Oslo	Norway
Hopital Necker Enfants Malades	Paris	France
Hospital Universitario De Navarra	Pamplona	Spain
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari	Bari	Italy

Other Sites

Site Name	City	Country
Karolinska University Hospital	Solna	Sweden
Centre Hospitalier Universitaire De Nantes	Nantes	France
Hopital Beaujon	Clichy	France
Klinikum Wels-Grieskirchen GmbH	Wels	Austria
Danderyds Sjukhus AB	Danderyd	Sweden
Centre Hospitalier De Valenciennes	Valenciennes	France
Centre Hospitalier Du Puy	Le Puy-En-Velay	France
Niyjm Ezrgrmz Mkfjepn Cqbdbq Ffjhrlycmm	Tallin	Estonia
Aebqesidoc Pdahqnrf Hijnspvp Di Mnuwytlrb	Marseille	France
Uigtqfi Ujeogcwlcn Hepeyeua	Uppsala	Sweden
Hkqwu Busuue Hn	Bergen	Norway
Cwgsdub Ucjzfjqosqrqttxdsogj Bfavhg Kzm	Berlin	Germany
Vxborvov ulrpssizkiit llrigrtt Soolmiev kbctbkhe Vtf	Vilnius	Lithuania
Ftjdrrxw Naujbcypt Bxsv	Brno	Czechia
Hhjbgmtf Uutwgyjvaxhfl Ffgjtezaa Jbvvznb Dulq	Madrid	Spain
Utkudnotmstz Dx Srlxkhur Ds Coqhnpdbtw	Santiago De Compostela	Spain
Axcddbq Upbrxeihnm Haziafyp	Aalborg	Denmark
Nribxqhiz Amle Ntpg Jlhzt ahru	Novy Jicin	Czechia
Uccwieskvtmj Lngzcnl	Leipzig	Germany
Rakhohcueeqjau	Copenhagen	Denmark
Psfgpkxqwue Skslmm dwxidr	Zagreb	Croatia
Uweabltmhogi Mipxrhy Chbvvrp Ggnbjkalk	Groningen	The Netherlands
Udkoconxyyatkhmkdlyrk Aqszki Ahs	Aachen	Germany
Hrzamzbp Ummxscrxvurkm Pheugx Dj Hypgvg Dr Myqmdzzvnkl	Majadahonda	Spain
Aiwcemof Zwclwvjnce Doofc	Roeselare	Belgium
Qmbzl Sxbwfq Coochhzbf Hocwjpbb &amxkat Snrmunjjsok Uvbzxnvjns Hetisnqt &ilwywx Vinsncf Gffyyoyqlhvhrzqaqj	Gothenburg	Sweden
Pycrq Syshdnci Cnfvvhgq Usbogfxoig Htnsrzof	Riga	Latvia
Sbr Smj z oclk	Cracow	Poland
Ipyduren db Ccjhmvsxvgyb Hcayghuyqzt Usntpwpofxsnm du Sqdbw Ebvllwv (rgivdxj	Saint Priest En Jarez	France
Cbkxon Hyrltazbszt Uandnotdtzkpq Dv Bltbexiu	Bordeaux	France
Ugokunwuxq On Boiehdqm	Talence	France
Tsfbp Umqmdibvpf Hugglvbo	Tartu	Estonia
Ktoeelzg Suj Guqvk gchhz	Leipzig	Germany
Sbcckdfgf Rxlgfnp Unuwiwevdl Msaowgs Ccdyce	Nijmegen	The Netherlands
Vcrzuqtsaklg Kttnbiqwdwmbcqmwfpcxandxbnjpbegj myx	Feldkirch	Austria
Uqtqxyqrhf Hbfexait Gznqrs	Galway	Ireland
Htklxzmm Udcwfqlgqpvj Albrb De Vyolxlyf Do Lq Gsdmtpwp Tnyrjkqzdfc De Lzkvhy	Lleida	Spain
Pybfpaplz Izzkwsgl Mdrxcgzz Mfslopddnjqo Swpvz Waofbbulgzii I Aajfqkolpgjrg	Warsaw	Poland
Vneflwpf Srkumwkf Sla	Valmiera	Latvia
Zxctygqfxr Onzk Lykeruy	Genk	Belgium
Uwlvqdasbp Op Psvv	Pecs	Hungary
Supgeqs Ow	Kuopio	Finland
Puckpuvrwh hfnordmwjjfngus	Tampere	Finland
Rjsaji Oigwwrtbjdpzzs	Linkoping	Sweden
Ckyt Upcszrpxst Hjvaoyvw	Cork	Ireland
Lxhjhgzw snulsmtzt mivnqh ukislhooccod lvhcbrxf Kkqfc kqvujomx	Kaunas	Lithuania
Uswunwsjpz Hthuptmj Wyfajcomd	Waterford	Ireland
Hbawbvzn Ujvbccuvfzxrs De Pcpiw Allhvxjvkg	Valencia	Spain
Cepbjsks Hcdyruny Danrkry	Zagreb	Croatia
Unagyioivn Hqrqtvgu Mshszm	Zagreb	Croatia

Trial status

Country	Status	Recruitment Start
Austria	Not recruiting	01.11.2024
Belgium	Not recruiting	01.11.2024
Croatia	Not recruiting	01.11.2024
Czechia	Not recruiting	01.11.2024
Denmark	Not recruiting	01.11.2024
Estonia	Not recruiting	01.11.2024
Finland	Not recruiting	01.11.2024
France	Not recruiting	01.11.2024
Germany	Not recruiting	01.11.2024
Hungary	Not recruiting	01.11.2024
Ireland	Not recruiting	01.11.2024
Italy	Not recruiting	01.11.2024
Latvia	Not recruiting	01.11.2024
Lithuania	Not recruiting	01.11.2024
Norway	Not recruiting	01.11.2024
Poland	Not recruiting	01.11.2024
Spain	Not recruiting	01.11.2024
Sweden	Not recruiting	01.11.2024
The Netherlands	Not recruiting	01.11.2024

Trial locations

Investigated Drugs:

Povetacicept

Povetacicept is a medication being studied for its potential to help people with a kidney condition called Immunoglobulin A Nephropathy. This condition can cause damage to the kidneys over time. Povetacicept is designed to reduce the amount of protein in the urine, which is a sign of kidney damage. By lowering protein levels in the urine, the medication aims to protect the kidneys and help them function better for a longer period. The study is looking at how well Povetacicept works compared to a placebo, which is a substance with no active medication, to see if it can effectively preserve kidney function in patients with this condition.

Investigated Diseases:

Nephropathy

Immunoglobulin A Nephropathy – Immunoglobulin A Nephropathy is a kidney disease that occurs when the antibody immunoglobulin A (IgA) builds up in the kidneys. This buildup causes inflammation that can affect the kidneys’ ability to filter waste from the blood. Over time, the inflammation can lead to kidney damage. The disease often progresses slowly over many years. Symptoms may include blood in the urine, protein in the urine, and swelling in the hands and feet. As the disease progresses, it can lead to chronic kidney disease.

Trial ID:

2024-514135-17-00

Protocol code:

AIS-D08

NCT ID:

NCT06564142

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effects of Povetacicept for Adults with IgA Nephropathy

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?